Icon
+91 94997 68112
Login Register

Qudexy XR - (25,50,100,150,200 mg; Capsule, Extended Release)

Topiramate Upsher Smith
25,50,100,150,200 mg; Capsule, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
Less Than 5
Indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures and adjunctive therapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures
Yes
***** ****** ** *** ***** ** **** **** ** **** ******* '***, ’***, *** ’*** *** ***** ******** ** ***** **, **** *** *** ************ *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** ****** ********* ** *** ***** ** ***** ****** *** ****** *** ******* ** ***** **, ****. *****, ******** ***** **** ** **** '***, '***, '*** & '*** *** ******** ** ***** **, **** *** *** ********* ******* *** ********** *** ******* **** ******** ** **** ***** *** ***** ** ********** *** *** *****.
Qudexy XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
***** ****** ******* ******* ******* ******* *** ********* (***** ******)
******** ******* ******* ******* ******* *** ********* (***** ******)
****** ** ****** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ** *** *, **** ******* ******** ******** *** **, ****
******** ** \ ** *** **, **** ******* ******** ******** ** *** *, ****
****** ** ****** ** \ ** *** **, **** ******* ********* ******** *** ****** *** ****
  1. *** **, **** : ***** ****** ******** ****** ***** ***** *** **** ** **** ******* '***, ’***, *** ’*** *** ***** ******** ** ***** **, ****.
  2. *** *, **** : ****** ***** ***** * **** ******* ***** ****** ** ******** ***** ** ********.
  3. *** **, **** : ********** *** ******* **** ***** ****** ********* ** *** ***** ** ***** ****** *** ****** *** ******* ** ***** **, ****.
  4. *** **, **** : ******** ******** ****** ***** ********* **** ** **** *,***,***, *,***,***, *,***,***, *** *,***,*** ** ******* *** ******** ** ***** **, ****.
  5. *** **, **** : ****** ***** **** ******** ** ** ** ********.
  6. *** **, **** : ********** *** ********* **** ******** ***** *** ***** ** ********* *** *** ***** *** ** ****** ******** ** ****** * ****** ***** ******.
  7. *** *, **** : ******** ***** ******** ***** ******* *****://****.******.***/****/*/*/#*****/********************************?*********=*&*************=*.*
  8. *** **, **** : ****** ****** ******** ****** ***** ** ***** ****-** ****** **** ******* '***, '***, '***, *** '***.
  9. *** **, **** : ****** ***** **** ****** ****** **** ************ ** ******* '***, '***, '***, *** '***.
  10. *** *, **** : **** ******** ****** ***** ***** ** **** ** ****** ** ****** '***.
  11. *** **, **** : ****** ***** **** **** **** ************ ** ****** ** '***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.